Repligen Co. (NASDAQ:RGEN) Receives Average Rating of "Moderate Buy" from Analysts

Repligen Co. (NASDAQ:RGEN - Get Free Report) has been given a consensus rating of "Moderate Buy" by the thirteen research firms that are presently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $181.00.

A number of brokerages recently weighed in on RGEN. StockNews.com cut shares of Repligen from a "hold" rating to a "sell" rating in a research note on Friday, February 21st. JPMorgan Chase & Co. boosted their price target on shares of Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Wolfe Research began coverage on shares of Repligen in a report on Thursday, November 14th. They issued a "peer perform" rating for the company. Canaccord Genuity Group started coverage on Repligen in a report on Tuesday, December 17th. They set a "hold" rating and a $165.00 target price on the stock. Finally, Canaccord Genuity Group increased their price target on Repligen from $165.00 to $170.00 and gave the company a "hold" rating in a research note on Friday, February 21st.

Repligen Stock Performance

NASDAQ RGEN traded up $2.44 on Monday, hitting $160.11. The stock had a trading volume of 589,073 shares, compared to its average volume of 611,422. The company's 50-day moving average is $157.02 and its two-hundred day moving average is $148.62. The stock has a market cap of $8.97 billion, a price-to-earnings ratio of -313.94, a P/E/G ratio of 4.54 and a beta of 0.99. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen has a one year low of $113.50 and a one year high of $203.13.

Remove Ads

Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.41 by $0.03. The firm had revenue of $167.55 million for the quarter, compared to analysts' expectations of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. On average, analysts expect that Repligen will post 1.72 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in RGEN. Creative Planning lifted its position in shares of Repligen by 32.6% in the 3rd quarter. Creative Planning now owns 5,123 shares of the biotechnology company's stock valued at $762,000 after acquiring an additional 1,259 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Repligen by 133.2% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 4,009 shares of the biotechnology company's stock valued at $597,000 after purchasing an additional 2,290 shares in the last quarter. State of Alaska Department of Revenue boosted its position in shares of Repligen by 7.3% in the third quarter. State of Alaska Department of Revenue now owns 6,044 shares of the biotechnology company's stock worth $899,000 after buying an additional 410 shares during the period. Americana Partners LLC purchased a new position in shares of Repligen during the third quarter valued at $203,000. Finally, QRG Capital Management Inc. grew its holdings in shares of Repligen by 12.5% during the third quarter. QRG Capital Management Inc. now owns 3,642 shares of the biotechnology company's stock valued at $542,000 after buying an additional 406 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.